New drug combo takes on Hard-to-Treat cancers in first human test

NCT ID NCT06131398

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and look for early signs that the tumors shrink. Because it's a Phase 1 study, the focus is on safety and dosing, not yet on proving the drug works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AMG 355 (an experimental drug) and pembrolizumab (Keytruda, an immunotherapy)

What this could lead to

If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.

What could go wrong

This is a very early Phase 1 trial with only 77 participants, so the main goal is safety and dosing — not yet proving the drug works. Many experimental cancer drugs fail in early testing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm gastric neoplasm melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Show contact details

Locations

Alliance for Multispecialty Research - Kansas City

Merriam, Kansas, 66204, United States
Asan Medical Center

Seoul, 138-736, South Korea
City of Hope National Medical Center

Duarte, California, 91010, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Erasmus Medisch Centrum

Rotterdam, 3015 CE, Netherlands
Gustave Roussy

Villejuif, 94805, France
Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Universitari Vall d Hebron

Barcelona, Catalonia, 08023, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Institut Bergonie

Bordeaux, 33076, France
Istituto Oncologico della Svizzera Italiana

Bellinzona, 6500, Switzerland
Kantonsspital Sankt Gallen

Sankt Gallen, 9007, Switzerland
Narodowy Instytut Onkologii im Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

Warsaw, 02-781, Poland
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 1Z5, Canada
Radboud Universitair Medisch Centrum

Nijmegen, 6525 GA, Netherlands
Seoul National University Hospital

Seoul, 03080, South Korea
South Texas Accelerated Research Therapeutics

San Antonio, Texas, 78229, United States
St Vincents Hospital Sydney

Darlinghurst, New South Wales, 2010, Australia
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koto-ku, Tokyo, 135-8550, Japan
The Queen Elizabeth Hospital

Woodville South, South Australia, 5011, Australia
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States
Washington University

St Louis, Missouri, 63110, United States